Stockscreener 앱 받기
37.89
1.77%
-0.68
전일 마감가:
$38.57
열려 있는:
$38.73
하루 거래량:
1.02M
Relative Volume:
0.34
시가총액:
$6.81B
수익:
$217.77M
순이익/손실:
$-438.86M
주가수익비율:
-15.72
EPS:
-2.41
순현금흐름:
$-456.33M
1주 성능:
+5.56%
1개월 성능:
+20.77%
6개월 성능:
+48.45%
1년 성능:
+36.13%
1일 변동 폭
$37.76
$38.73
1주일 범위
$35.67
$39.54
52주 변동 폭
$21.62
$39.54
Bridgebio Pharma Inc Stock (BBIO) Company Profile
명칭
Bridgebio Pharma Inc
전화
(650) 391-9740
주소
3160 PORTER DR., PALO ALTO, CA
BBIO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
37.90 | 6.81B | 217.77M | -438.86M | -456.33M | -2.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.81 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.91 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
655.71 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
269.34 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.24 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-31 | 개시 | Redburn Atlantic | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-10-03 | 개시 | Oppenheimer | Perform |
| 2024-09-04 | 개시 | Piper Sandler | Overweight |
| 2024-03-21 | 재개 | Raymond James | Outperform |
| 2024-01-31 | 개시 | BMO Capital Markets | Market Perform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-11-07 | 개시 | Citigroup | Buy |
| 2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-07-18 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-04-19 | 개시 | Evercore ISI | Outperform |
| 2023-02-06 | 개시 | Cowen | Outperform |
| 2021-12-27 | 재확인 | Mizuho | Buy |
| 2021-12-27 | 재확인 | SVB Leerink | Outperform |
| 2021-09-10 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2021-05-21 | 개시 | UBS | Buy |
| 2021-03-22 | 재확인 | Goldman | Buy |
| 2021-02-22 | 재개 | JP Morgan | Overweight |
| 2021-02-09 | 재개 | Goldman | Buy |
| 2021-01-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-10 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-25 | 개시 | BofA/Merrill | Neutral |
| 2020-05-19 | 개시 | BTIG Research | Buy |
| 2020-04-13 | 개시 | H.C. Wainwright | Buy |
| 2020-02-19 | 개시 | Mizuho | Buy |
| 2019-07-26 | 개시 | Raymond James | Outperform |
| 2019-07-22 | 개시 | BMO Capital Markets | Outperform |
| 2019-07-22 | 개시 | Goldman | Buy |
| 2019-07-22 | 개시 | JP Morgan | Overweight |
| 2019-07-22 | 개시 | Jefferies | Buy |
| 2019-07-22 | 개시 | Piper Jaffray | Overweight |
| 2019-07-22 | 개시 | SVB Leerink | Outperform |
모두보기
Bridgebio Pharma Inc 주식(BBIO)의 최신 뉴스
Achondroplasia Market: Epidemiology, Therapies, Companies, - openPR.com
Mizuho Adjusts Price Target on BridgeBio Pharma to $60 From $53, Maintains Outperform Rating - marketscreener.com
Alnylam Delivers Q1 Surprise, Analysts Highlight Amvuttra Momentum, Limited Tariff Risk - Benzinga
BridgeBio (BBIO) Sees Surge in Bullish Option Activity | BBIO Stock News - GuruFocus
BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update - ADVFN
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Q1 2025 Earnings Call Transcript - Insider Monkey
High Growth Tech Stocks In The US Market May 2025 - simplywall.st
BridgeBio Pharma First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Why BridgeBio Pharma, Inc. (BBIO) Surged on Wednesday - MSN
Excellent Earnings Propelled Prices of These 10 Firms - Insider Monkey
BridgeBio Takes A Victory Lap With First Full Quarter Of Attruby Sales - insights.citeline.com
Decoding BridgeBio Pharma Inc (BBIO): A Strategic SWOT Insight - GuruFocus
BridgeBio sales of new heart drug outstrip expectations - BioPharma Dive
BridgeBio (BBIO) Price Target Increased by Scotiabank Analyst | - GuruFocus
Attruby's Momentum and an Advancing Pipeline Support BridgeBio's Long-Term Growth Outlook - Morningstar
UBS Raises Price Target for BridgeBio (BBIO) Amid Strong Q1 Perf - GuruFocus
UBS Adjusts Price Target on BridgeBio Pharma to $72 From $65, Maintains Buy Rating - marketscreener.com
Scotiabank raises BridgeBio stock target to $55 on strong sales By Investing.com - Investing.com India
BridgeBio (BBIO) Price Target Uplifted by BofA Analyst Amid Stro - GuruFocus
Scotiabank raises BridgeBio stock target to $55 on strong sales - Investing.com
BridgeBio price target raised to $63 from $46 at Piper Sandler - TipRanks
BridgeBio (BBIO) Target Price Increased by Piper Sandler Followi - GuruFocus
BridgeBio (BBIO) Target Price Increased by Piper Sandler Following Strong Quarter | BBIO Stock News - GuruFocus
BridgeBio’s Attruby outperforms sales expectations, shares rise - Endpoints News
BridgeBio Pharma’s Attruby Outperforms Expectations, Analyst Raises Price Target to $50 - TipRanks
(BBIO) Trading Advice - news.stocktradersdaily.com
BridgeBio Pharma Inc (BBIO) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
BridgeBio Pharma Inc (BBIO) Q1 2025 Earnings Call Highlights: St - GuruFocus
BridgeBio Pharma: Q1 Earnings Snapshot - CT Insider
BridgeBio Pharma Reports Q1 2025 Earnings and Pipeline Progress - TipRanks
Earnings call transcript: BridgeBio Q1 2025 shows strong revenue growth By Investing.com - Investing.com Nigeria
Earnings call transcript: BridgeBio Q1 2025 shows strong revenue growth - Investing.com
BridgeBio Pharma, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:BBIO) - Seeking Alpha
BridgeBio Pharma (BBIO) Reports Strong Q1 Earnings, Shares Rise - GuruFocus
BridgeBio Pharma (BBIO) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
BridgeBio Pharma, Inc. SEC 10-Q Report - TradingView
BridgeBio Pharma Q1 Loss Widens, Revenue Drops - marketscreener.com
BridgeBio (BBIO) Exceeds Revenue Expectations with Strong Prescr - GuruFocus
BridgeBio Reports First Quarter 2025 Financial Results and Business Updates - The Manila Times
BridgeBio Reports Blockbuster Q1: New Drug Attruby Surges with 2,072 Patient Scripts, Pipeline Advances - Stock Titan
BridgeBio (BBIO) Anticipates Significant Post-Earnings Volatilit - GuruFocus
BridgeBio Pharma, Inc. (BBIO): Among Billionaire Andreas Halvorsen’s Stock Picks With Huge Upside Potential - MSN
UK MHRA authorises BridgeBio’s acoramidis for ATTR-CM - Yahoo
BridgeBio Pharma (BBIO) Set to Release Q1 Earnings Report - GuruFocus
BridgeBio Pharma Inc (BBIO) Q1 2025 Earnings Report Preview: Wha - GuruFocus
A Look Ahead: BridgeBio Pharma's Earnings Forecast - Benzinga
Transthyretin Amyloid Cardiomyopathy Treatment Market Size - openPR.com
Pinning Down BridgeBio Pharma, Inc.'s (NASDAQ:BBIO) P/S Is Difficult Right Now - simplywall.st
BridgeBio (BBIO) Gains UK Approval for Cardiomyopathy Drug | BBI - GuruFocus
BridgeBio Pharma's Beyonttra Approved in UK for Heart Condition due to Amyloidosis - marketscreener.com
BEYONTTRA® (acoramidis), the First Near-complete TTR Stabilizer - GuruFocus
Bridgebio Pharma Inc (BBIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Bridgebio Pharma Inc 주식 (BBIO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Kumar Neil | Chief Executive Officer |
Apr 22 '25 |
Sale |
34.11 |
75,000 |
2,558,025 |
4,873,447 |
| Ellis Andrea | Director |
Apr 14 '25 |
Option Exercise |
8.45 |
10,000 |
84,500 |
22,000 |
| Ellis Andrea | Director |
Apr 14 '25 |
Sale |
35.00 |
10,000 |
350,000 |
12,000 |
0.08%
0.47%
자본화:
|
볼륨(24시간):